Khoja Hamid
Known title: Chief Scientific OfficerCIK: 0002010662
Khoja Hamid's purchase track record
How the stock did after each of Khoja Hamid's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since August 12, 2024
Stock higher 6 months later
0%
3 months: 33%
Median 6-month return
-67.0%
3 months: -25.5%
Beat the S&P 500
0%
median -81.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/4/2026 | FBLG | $11K | -85.8% | -74.1% | +11.6% |
| 5/27/2025 | FBLG | $17K | -25.5% | -67.0% | +14.3% |
| 8/12/2024 | FBLG | $19K | +88.5% | -3.3% | +13.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| FBLG | ▲ Buy | Grant | 298,508 | $500K | 9/15/2026 | View on chart |
| FBLG | ▲ Buy | Open Market | 30,000 | $11K | 3/4/2026 | View on chart |
| FBLG | ▲ Buy | Open Market | 20,000 | $17K | 5/27/2025 | View on chart |
| FBLG | ▲ Buy | Open Market | 10,000 | $19K | 8/12/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
FibroBiologics Secures European Patent for Fibroblast Methods
FibroBiologics announced the grant of a European patent for methods enhancing fibroblast therapeutic activity. This development strengthens the company's intellectual property portfolio in Europe. The stock is currently trading near its 52-week low, significantly below the average analyst target price.
FibroBiologics Secures European Patent for Fibroblast Methods. FibroBiologics announced the grant of a European patent for methods enhancing fibroblast therapeutic activity. This development strengthens the company's intellectual property portfolio in Europe. The stock is currently trading near its 52-week low, significantly below the average analyst target price.